Current Insights on Lipid-Based Nanosystems

Lipid-based nanosystems, including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), cationic lipid nanoparticles, nanoemulsions, and liposomes, have been extensively studied to improve drug delivery through different administration routes. The main advantages of these syste...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (368 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 05614nam-a2201405z--4500
001 993576086104498
005 20231214132827.0
006 m o d
007 cr|mn|---annan
008 202301s2022 xx |||||o ||| 0|eng d
020 |a 3-0365-6165-X 
035 |a (CKB)5470000001633402 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/95900 
035 |a (EXLCZ)995470000001633402 
041 0 |a eng 
100 1 |a Silva, Ana Catarina  |4 edt 
245 1 0 |a Current Insights on Lipid-Based Nanosystems 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (368 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Lipid-based nanosystems, including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), cationic lipid nanoparticles, nanoemulsions, and liposomes, have been extensively studied to improve drug delivery through different administration routes. The main advantages of these systems are their ability to protect, transport, and control the release of lipophilic and hydrophilic molecules (either small-molecular-weight molecules or macromolecules); the use of generally recognized as safe (GRAS) excipients that minimize the toxicity of the formulations; and the possibility to modulate pharmacokinetics and enable the site-specific delivery of encapsulated payloads. In addition, the versatility of lipid-based nanosystems has further been demonstrated for the delivery of vaccines, the protection of active cosmetic ingredients, and the improvement of moisturizing properties of cosmetic formulations.Lipid-based nanosystems are well established and there are already different commercially approved formulations for various human disorders. This success has paved the way for the diversification of the pipeline of development, to address unmet medical needs for several indications, such as cancer, neurological disorders, and autoimmune, genetic, and infectious diseases.This Special Issue aims to update readers on the latest research on lipid-based nanosystems, both at the preclinical and clinical levels. A series of 15 articles (six reviews and nine studies) is presented, with authors from 12 different countries, showing the globality of the investigations that are being carried out in this area. 
546 |a English 
650 7 |a Technology: general issues  |2 bicssc 
653 |a Echinococcus granulosus 
653 |a scolicidal 
653 |a nanoliposome 
653 |a juglone 
653 |a apoptotic activity 
653 |a hydrogel 
653 |a SLNs 
653 |a nose-to-brain delivery 
653 |a mucoadhesion 
653 |a quality by design 
653 |a antioxidant activity 
653 |a nasal administration 
653 |a nanostructured lipid carriers 
653 |a solid lipid nanoparticles 
653 |a in vitro cell cultures 
653 |a 3D nasal casts 
653 |a lung cancer 
653 |a targeted drug delivery 
653 |a lipid-based nanocarriers 
653 |a pulmonary delivery 
653 |a dry powder inhalers 
653 |a aerosols 
653 |a liposomes 
653 |a nanoemulsions 
653 |a nanotechnology 
653 |a biologically active compounds 
653 |a dermal drug delivery 
653 |a polyphenols 
653 |a phytophenols 
653 |a skin permeation 
653 |a chemotherapy 
653 |a radiotherapy 
653 |a active targeting 
653 |a passive targeting 
653 |a tumor 
653 |a immunoconjugate 
653 |a traditional liposome 
653 |a stealth liposome 
653 |a triggered release 
653 |a limitations of liposomes 
653 |a drug transfer 
653 |a in vitro release 
653 |a colloidal drug carriers 
653 |a lipid nanoparticles 
653 |a hydrogel beads 
653 |a cholesteryl nonanoate 
653 |a bovine serum albumin 
653 |a skin diseases 
653 |a lipid-based nanosystems 
653 |a cream 
653 |a ointment 
653 |a gel 
653 |a pH-sensitive 
653 |a liposome 
653 |a imidazole 
653 |a anticancer 
653 |a drug delivery 
653 |a multicellular spheroids 
653 |a dapagliflozin 
653 |a Box-Behnken design 
653 |a FTIR 
653 |a DSC 
653 |a XRD 
653 |a SEM 
653 |a AFM 
653 |a in vitro Franz diffusion cells 
653 |a lipid-based nanoparticles 
653 |a nanocarrier 
653 |a surface charge 
653 |a delivery systems 
653 |a chronic treatment 
653 |a mice 
653 |a anti-oxidant activity 
653 |a hepatoprotective effect 
653 |a phospholipid 
653 |a phytosomes 
653 |a Silymarin 
653 |a Colorectal Cancer 
653 |a Niosomes 
653 |a Oxaliplatin 
653 |a Paclitaxel 
653 |a d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) 
653 |a therapeutic nucleic acids 
653 |a schizophrenia 
653 |a quetiapine fumarate 
653 |a glycerosomes 
653 |a central composite rotatable design 
653 |a bioavailability 
653 |a pharmacokinetic 
776 |z 3-0365-6166-8 
700 1 |a Moreira, João  |4 edt 
700 1 |a Sousa Lobo, José Manuel  |4 edt 
700 1 |a Silva, Ana Catarina  |4 oth 
700 1 |a Moreira, João  |4 oth 
700 1 |a Sousa Lobo, José Manuel  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:32:28 Europe/Vienna  |f system  |c marc21  |a 2023-01-18 06:03:23 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5345740790004498&Force_direct=true  |Z 5345740790004498  |b Available  |8 5345740790004498 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5342444980004498&Force_direct=true  |Z 5342444980004498  |b Available  |8 5342444980004498